References


References

Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssiere L; Oksman F; Durand D; Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005 Dec 15; 80(11):1560-4.

Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssiere L; Oksman F; Durand D; Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation. 2005 Dec 15; 80(11):1560-4.


Berthoux F; El Deeb S; Mariat C; Diconne E; Laurent B; Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation. 2008 May 27; 85(10):1505-7.

Bhalla V; Nast CC; Stollenwerk N; Tran S; Barba L; Kamil ES; Danovitch G; Adler SG. Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation. 2003 Jan 15; 75(1):66-71.


Brennan DC. Faith supported by reason: mechanistic support for the use of polyclonal antibodies in transplantation. Transplantation 2003; 75:577-582.


Burdmann EA; Andoh TF; Yu L; Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003 Sep;23(5):465-76.


Cecka JM. Results of more than 1000 recent living-unrelated donor transplants in the United States. Transplant Proc 1999; 31: 234.


Cheigh JS; Mouradian J; Susin M; Stubenbord WT; Tapia L; Riggio RR; Stenzel KH; Rubin AL. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980 Sep;18(3):358-65.


Choi MJ; Eustace JA; Gimenez LF; Atta MG; Scheel PJ; Sothinathan R; Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002 Mar; 61(3):1098-114.


Gallon L; Perico N; Dimitrov BD; Winoto J; Remuzzi G; Leventhal J; Gaspari F; Kaufman D. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression


Gerald Opelz, MD, Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany, personal communication, July 2006, American Society of Transplantation Annual Meeting, Boston, MA.


Glicklich D; Matas AJ; Sablay LB; Senitzer D; Tellis VA; Soberman R; Veith FJ. Recurrent membranoproliferative glomerulonephritis type 1 in successive renal transplants. Am J Nephrol 1987;7(2):143-9.


Heering P; Braun N; Mullejans R; Ivens K; Zauner I; Funfstuck R; Keller F; Kramer BK; Schollmeyer P; Risler T; Grabensee B. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004 Jan; 43(1):10-8.


Jais JP; Knebelmann B; Giatras I; De Marchi M; Rizzoni G; Renieri A; Weber M; Gross O; Netzer KO; Flinter F; Pirson Y; Verellen C; Wieslander J; Persson U; Tryggvason K; Martin P; Hertz JM; Schroder C; Sanak M; Krejcova S; Carvalho MF; Saus J; Antignac C; Smeets H; Gubler MC. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000 Apr; 11(4):649-57.


References


Kim YS; Moon JI; Jeong HJ; Kim MS; Kim SI; Choi KH; Lee HY; Han DS; Park K. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001 Jan 27; 71(2):233-8.


Kowalewska J; Yuan S; Sustento-Reodica N; Nicosia RF; Smith KD; Davis CL; Alpers CE. IgA nephropathy with crescents in kidney transplant recipients. Am J Kidney Dis 2005 Jan; 45(1):167-75.


Little MA; Dupont P; Campbell E; Dorman A; Walshe JJ. Severity of primary MPGN determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006 Feb; 69(3):504-11.


Matas A: Recurrent disease after kidney transplantation: It is time to unite to address this problem! Am J Transplant 2006; 6: 2527–2528.


McLean RH; Geiger H; Burke B; Simmons R; Najarian J; Vernier RL; Michael AF. Recurrence of membranoproliferative glomerulonephritis following kidney transplantation. Serum
References


Meehan SM; Pascual M; Williams WW; Tolkoff-Rubin N; Delmonico FL; Cosimi AB; Colvin RB SO: De novo collapsing glomerulopathy in renal allografts. Transplantation 1998 May 15; 65 (9):1192-7.

Meier-Kriesche, HU, Schold, JD, Srinivas, TR, Kaplan, B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.


Mizutani K, Terasaki P, Hamdani E. The importance of anti-HLA-
specific antibody strength in monitoring kidney transplant

Molina MG, Seron D, del Moral R, et al. Mycophenolate mofetil reduces
deterioration of renal function in patients with chronic allograft
nephropathy. A follow-up study by the Spanish Cooperative
Study Group of Chronic Allograft Nephropathy. Transplantation

Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from
transplanting incompatible live kidney donor/recipient pairs using

Morales JM, Pascual-Capdevila J, Campistol JM, et al: Membranous
glomerulonephritis associated with hepatitis C virus in renal

Morales JM; Martinez MA; Munoz de Bustillo E; Munoz MA; Gota R;
Usera G. Recurrent type III membranoproliferative
glomerulonephritis after kidney transplantation. Transplantation

Muczynski KA. Plasmapheresis maintained renal function in an allograft
with recurrent membranoproliferative glomerulonephritis type I.

Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-
705.


Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide

Ponticelli C; Minetti L; Di Palo FQ; Vegeto A; Belli L; Corbeta G; Tarantino A; Civati G. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988 May; 45(5):908-13.

Ponticelli C; Zucchelli P; Passerini P; Cesana B; Locatelli F; Pasquali S; Sasdelli M; Redaelli B; Grassi C; Pozzi C. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995 Nov; 48(5):1600-4.


Roth D; Cirocco R; Zucker K; Ruiz P; Viciana A; Burke G; Carreno M; Esquenazi V; Miller J. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995 Jun 27; 59(12):1676-82.


Schwarz A; Krause PH; Offermann G; Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after


Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J Jr; First MR. Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study. Transplantation 2008 May 15; 85(9):1261-1269.

Shimmura H, Tanabe K, Ishida H, et al. Lack of correlation between results of ABO-incompatible living kidney transplants and anti-


Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007 Mar; 7(3):586-94.


Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007 May; 2(3):445-53.


Webster AC; Woodroffe RC; Taylor RS; Chapman JR; Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005 Oct 8;331(7520):810.


References

Woodward RS; Kutinova A; Schnitzler MA; Brennan DC. Renal graft survival and calcineurin inhibitor. Transplantation 2005 Sep 15; 80(5):629-33.


